Detalles de la búsqueda
1.
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial.
Lancet Oncol
; 24(12): 1359-1374, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37926100
2.
Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial.
Cancer
; 127(5): 700-708, 2021 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33290610
3.
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer.
Breast Cancer Res Treat
; 187(1): 155-165, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33591468
4.
Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial.
Breast Cancer Res Treat
; 185(3): 697-707, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33159633
5.
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
Lancet Oncol
; 21(6): 763-775, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32353342
6.
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.
Lancet Oncol
; 21(10): 1296-1308, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32919527
7.
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
Lancet
; 393(10191): 2599-2612, 2019 06 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-31178152
8.
Health-related quality of life and work productivity in UK patients with HER2-positive breast cancer: a cross-sectional study evaluating the relationships between disease and treatment stage.
Health Qual Life Outcomes
; 18(1): 353, 2020 Nov 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33138835
9.
Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results.
BMC Cancer
; 18(1): 391, 2018 04 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29621991
10.
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.
Lancet Oncol
; 18(7): 929-945, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28600210
11.
Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.
Lancet Oncol
; 18(6): 755-769, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28479233
12.
Patient-derived Mammosphere and Xenograft Tumour Initiation Correlates with Progression to Metastasis.
J Mammary Gland Biol Neoplasia
; 21(3-4): 99-109, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27680982
13.
Trastuzumab-associated cardiac events in the Persephone trial.
Br J Cancer
; 115(12): 1462-1470, 2016 Dec 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27875516
14.
Protective strategies to prevent trastuzumab-induced cardiotoxicity - Authors' reply.
Lancet
; 395(10223): 492-493, 2020 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32061290
15.
CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).
Lancet Oncol
; 14(3): 244-8, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23414588
16.
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial.
Lancet Oncol
; 14(10): 989-98, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23902874
17.
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.
Lancet Oncol
; 14(1): 72-80, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23246022
18.
Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer.
Clin Cancer Res
; 30(4): 895-903, 2024 02 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38078899
19.
A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer.
Breast Cancer Res Treat
; 139(2): 411-9, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23649189
20.
Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study.
NPJ Breast Cancer
; 9(1): 81, 2023 Oct 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37803017